Full Year Result 2016
CSL Delivers Another Strong Performance

Full Year Result 2016
CSL Delivers Another Strong Performance

Melbourne, Australia — 17/08/2016

  • Double-digit sales growth in all plasma therapy groups
  • Novel recombinant coagulation products approved and launched
  • Seqirus formed – business turnaround program on track
  • CSL Board to consider further share buyback of ~A$500 million
Full Year Results Announced 2016

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016. After excluding the financials relating to the Novartis influenza vaccines business acquired during the year, underlying1 NPAT grew 5% and earnings per share (EPS) grew 7% on a constant currency (CC)2 basis.

HIGHLIGHTS

Financial

  • Revenue US$6,129 million
    • Underlying revenue up 8% at CC
  • Earnings before interest and tax (EBIT) US$1,438 million
    • Underlying EBIT up 7% at CC
  • NPAT US$1,242 million
    • Underlying NPAT up 5% at CC
  • EPS US$2.69
    • Reported EPS down 8%
    • Underlying EPS up 7% at CC
  • Research and development investment US$614 million
  • Final dividend3 of US$0.68 per share, up 3% on PCP
    • Unfranked for Australian tax purposes, payable on 7 October 2016
    • Converted to Australian currency, the final dividend is approximately A$0.89 per share

Download this release: 
PDF icon CSL Full Year results announcement for 2016   (0.2Mb)

Additional resources:
Details about CSL's results are included in the company's 4E statement, investor presentation slides and webcast. More ...

For further information, please contact:

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
Media:
  Jemimah Pentland
  Head of Asia Pacific Communications
  CSL Limited
  Phone: +613 9389 3473
  Mobile: +61 412 635 483
  Email: Jemimah.Pentland@csl.com.au




1 Underlying excludes financials relating to the Novartis influenza vaccines business (NVS-IV). NVS-IV was acquired on 31 July 2015. See end note for further detail.
2 Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.
3 For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.886652 per share (at an exchange rate of A$1.3039/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.943364 per share (at an exchange rate of NZ$1.3873/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$.

© 2017 CSL Limited